Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
Name:
37010651.pdf
Size:
1.385Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Dave, Rajiv VElsberger, B.
Taxiarchi, V. P.
Gandhi, Ashu
Kirwan, Cliona C
Kim, B.
Camacho, E. M.
Coles, C. E.
Copson, E.
Courtney, A.
Horgan, K.
Fairbrother, P.
Holcombe, C.
Kirkham, J. J.
Leff, D. R.
McIntosh, S. A.
O'Connell, R.
Pardo, R.
Potter, S.
Rattay, T.
Sharma, N.
Vidya, R.
Cutress, R. I.
Affiliation
The Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK.Issue Date
2023
Metadata
Show full item recordAbstract
Purpose: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources. Methods: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis. Results: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET. Discussion: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.Citation
Dave RV, Elsberger B, Taxiarchi VP, Gandhi A, Kirwan CC, Kim B, et al. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study. Breast Cancer Res Treat. 2023 Apr 3:1-15. PubMed PMID: 37010651. Pubmed Central PMCID: PMC10068712. Epub 2023/04/04. eng.Journal
Breast Cancer Research and TreatmentDOI
10.1007/s10549-023-06893-4PubMed ID
37010651Additional Links
https://dx.doi.org/10.1007/s10549-023-06893-4Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s10549-023-06893-4
Scopus Count
Collections
Related articles
- The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study.
- Authors: Martí C, Yébenes L, Oliver JM, Moreno E, Frías L, Berjón A, Loayza A, Meléndez M, Roca MJ, Córdoba V, Hardisson D, Rodríguez MÁ, Sánchez-Méndez JI
- Issue date: 2022 Mar 23
- The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
- Authors: Zhang A, Wang X, Fan C, Mao X
- Issue date: 2021
- Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?
- Authors: Iles KA, Thornton M, Park J, Roberson M, Spanheimer PM, Ollila DW, Gallagher K
- Issue date: 2022 Mar
- Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
- Authors: Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, Horgan K, Kirwan C, Mallon E, Sibbering M, Skene A, Vidya R, Cheang M, Banerji J, Morden J, Sidhu K, Dodson A, Bliss JM, Dowsett M
- Issue date: 2020 Nov
- Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
- Authors: Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K
- Issue date: 2017 Apr 1